|
Variables
|
Viral load
|
Unadjusted
|
Adjusted
|
|---|
|
Suppressed (n = 751, %)
|
Unsuppressed (80, %)
|
OR
|
95% CI
|
p
|
OR
|
95% CI
|
p
|
|---|
|
Baseline CD4 (cells/µl)
|
|
< 500
|
346 (46.1)
|
58 (72.5)
|
1
|
1.851, 5.146
|
< 0.001
|
1
|
1.588, 4.625
|
< 0.001
|
|
≥ 500
|
405 (53.9)
|
22 (27.5)
|
3.086
|
2.710
|
|
Years on HAART
|
|
< 5
|
325 (43.3)
|
29 (36.3)
|
1
|
0.462, 1.202
|
0.228
|
1
|
0.686. 2.019
|
0.555
|
|
≥ 5
|
405 (56.7)
|
51 (63.7)
|
0.745
|
1.117
|
|
HAART regimen
|
|
Second line
|
23 (3.1)
|
15 (18.8)
|
1
|
3.634, 14.683
|
< 0.001
|
1
|
3.220,15.648
|
< 0.001
|
|
First line
|
728 (96.9)
|
65 (81.3)
|
7.304
|
7.208
|
|
Disease stage
|
|
WHO stage 1 & 2
|
732 (97.5)
|
77 (96.3)
|
1
|
0.193, 2.302
|
0.521
|
–
|
–
|
–
|
|
WHO stage 3 & 4
|
19 (2.5)
|
3 (3.8)
|
0.666
|
|
Pregnancy status
|
|
Pregnant (20)
|
17 (3.3)
|
3 (5.0)
|
1
|
0.441, 5.455
|
0.494
|
–
|
–
|
–
|
|
Not pregnant (558)
|
501 (96.7)
|
57 (95.0)
|
1.551
|
- Variables included in the adjusted odds ratio were age, sex, occupation, educational status, BMI categories, baseline CD4 count, duration on HAART, and HAART regimens
- HAART-Highly active anti-retroviral therapy
